Delisting risk, souring relations are hurdles for Chinese biotech firms seeking to enter US market, analyst says

• Biotech industry in China and the US ‘will be shaped’ by bilateral tensions, says scholar at University of Pennsylvania
• Several Chinese biotech and pharmaceutical firms were added to a list of companies facing possible expulsion from US exchanges in March